TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
BOTHELL, Wash. - Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biotech with strong liquidity ratios and more cash than debt according to InvestingPro data, presented results from its Phase 1 clinical trial of ATH-1105 at the ALS Nexus 2025 conference in Dallas, showing favorable safety and tolerability profiles for its experimental treatment targeting amyotrophic lateral sclerosis (ALS).
The trial, which enrolled 80 healthy volunteers and was completed in November 2024, evaluated both single and multiple oral ascending doses of ATH-1105, a novel, orally available small molecule drug candidate designed to modulate the neurotrophic HGF system.
According to data presented at the conference, ATH-1105 demonstrated dose-proportional pharmacokinetics and central nervous system penetration, supporting further clinical development.
"The advancement of new treatment options for ALS is of vital importance to help prolong survival and improve quality of life of people living with ALS," said Javier San Martin, Chief Medical Officer at Athira, in the company’s press release.
The Phase 1 results were highlighted in a poster presentation titled "Safety, Tolerability, and Pharmacokinetics of ATH-1105 in Health Volunteers," presented by Kai-Bin Ooi, Director of Drug Development and Operations at the company.
ATH-1105 has also shown consistent effects in preclinical models of ALS, according to the company’s statement.
Athira Pharma, based in the Seattle area, focuses on developing small molecules aimed at restoring neuronal health and slowing neurodegeneration. The company’s pipeline includes drug candidates that modulate the neurotrophic HGF system for potential treatment of various neurodegenerative diseases.
The company has not yet announced specific plans for the next phase of clinical trials for ATH-1105.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.